Our advanced medicines aim to heal tissues and organs damaged by age, disease or traumas
Our initial focus is next-generation, high-value orthobiologics for spinal fusion (LB001) and degenerative disc disease (LB002), an area of core expertise.
Our lead program LB001 is a next generation, BMP-2 spinal fusion product, designed to reduce and control the dose of BMP2 required for spinal fusions. Our ‘injectable putty’ formulation enables minimally invasive surgery, as well as providing excellent handling characteristics for open surgery. Preclinical development will commence shortly to enable a first in man clinical study in 2022.
LB002 is a disease-modifying approach to DDD – degenerative disc disease, utilizing a novel combination of cell therapy and sustained anti-inflammatory activity.
We are also evaluating additional pipeline and partnering opportunities (e.g. localized, enhanced delivery of cell therapies to solid tumours) utilizing our novel proprietary technologies.
Team to make a difference
Our experienced team is passionate about developing advances medicines, capitalising on our increased understanding of our biology and new treatment modalities, to improve the lives of patients around the world.
Our core in-house scientific expertise in regenerative medicine and biomaterial-based drug, cell and gene delivery stems from the research of Professor Kevin Shakesheff (CSO) at the University of Nottingham.
Our novel technologies provide opportunities for potential disease modification or solutions through a multifaceted approach eg creating the right niche for cell therapies or otherwise modulating target tissues.
TAOS is an injectable, biodegradable, 3-D tissue matrix, designed as a local delivery system for small molecule, biologic, gene and cell therapies. The high macroporosity of TAOS allows endogenous cells and blood vessels to penetrate the matrix, or for exogenous cells such as MSCs and T cells to be delivered to patients.
IntraStem is a novel peptide based intracellular delivery (transfection) technology that overcomes key limitations of viral and non-viral delivery systems at present, including for gene therapy.
Our two technologies can be combined to deliver advanced therapies locally, either to:
- achieve high concentrations at the intended site of action; and or
- to reduce systemic availability, to improve safety and or efficacy; and or
- allow combination therapy to address complex diseases eg cell therapy augmented by drug therapy
Working with leaders in the regenerative medicine field
Locate has a pipeline agreement with the University of Nottingham which provides exclusive access to new technological breakthroughs through Locate’s scientific founder, Professor Kevin Shakesheff.
Our technologies were invented by world-leading regenerative medicine scientists in the UK and have been developed by Locate over several years.
Our TAOS® technology has been well validated through its use in several of our pipeline programs and we have established its manufacture in house. TAOS can be used in a wide range of tissue types and therapy areas, supported by promising in vivo data.
IntraStem™ has a broad range of potential applications, including gene therapy, and offers major advantages over current transfection technologies.
Locate is currently evaluating a number of new product opportunities for in-house development and for potential third party collaborations.